What's Happening?
The American Action Forum (AAF) has submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Draft Guidance on Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2028 under the Medicare Drug Price Negotiation Program.
Michael Baker, Director of Health Care Policy at AAF, emphasizes the need for careful implementation as MFP will apply to selected drugs payable under Medicare Part B for the first time. AAF recommends that CMS leverage existing Part B infrastructure for identifying MFP-eligible claims, calculating the Standard Default Refund Amount (SDRA), and managing the Medicare Transaction Facilitator (MTF). Specifically, AAF suggests using separate Healthcare Common Procedure Coding System (HCPCS) codes for MFP-eligible drugs, adopting an Average Sales Price (ASP)-based SDRA, and integrating the MTF with existing provider enrollment and payment systems like PECOS and MA encounter data.
Why It's Important?
The transition of MFP application to Medicare Part B presents unique challenges due to its distinct drug purchasing, coding, and payment systems compared to Part D. AAF's recommendations aim to minimize additional administrative and financial burdens on providers, manufacturers, and Medicare Advantage (MA) organizations. By utilizing existing infrastructure, CMS can avoid layering new reporting systems and transactional requirements, which could otherwise increase costs and complexity. For instance, using ASP as the basis for SDRA aligns with Congress's established methodology for Part B drug payment and is more closely tied to actual market transactions than wholesale acquisition cost (WAC). This approach seeks to ensure that the implementation of drug price negotiation is as efficient and least disruptive as possible, preventing unnecessary delays in MFP refunds and potential financial hardship for providers who acquire costly physician-administered drugs before reimbursement.
What's Next?
CMS will review the comments submitted by organizations like the American Action Forum as it finalizes the guidance for Manufacturer Effectuation of the Maximum Fair Price in 2028. The agency will need to decide on the specific methodologies for identifying MFP-eligible claims, calculating SDRAs, and integrating the MTF. AAF's recommendations suggest a preference for existing infrastructure, minimal new reporting, transparent methodologies, and predictable compliance rules. The outcome of these decisions will determine the administrative burden and operational efficiency of the Part B drug price negotiation program. CMS is also expected to establish clear compliance and reconciliation rules for SDRAs and monitor how well an ASP-based SDRA continues to approximate acquisition costs after Part B MFP effectuation begins, potentially adjusting requirements based on ongoing provider experience.
Beyond the Headlines
The detailed comments from the American Action Forum underscore the intricate operational challenges involved in implementing large-scale healthcare policy changes. Beyond the headline goal of drug price negotiation, the practicalities of execution can significantly impact the healthcare ecosystem. The debate over using existing infrastructure versus creating new systems highlights a broader tension between policy innovation and administrative stability. If CMS adopts AAF's suggestions, it could set a precedent for how future healthcare reforms are implemented, prioritizing integration and minimizing disruption. Conversely, a failure to streamline these processes could lead to increased administrative costs, delays in patient access to lower-priced drugs, and potential disincentives for providers. This situation illustrates that the success of healthcare policy often hinges on the granular details of its operationalization, affecting not just drug prices but the entire administrative framework of Medicare.
